Description
The global gene therapy market was valued at USD 3.2 billion in 2025 and is projected to grow from USD 16.3 billion in 2026 to USD 33.6 billion by 2032, expanding at a CAGR of 26.2% from 2026 to 2032. Gene therapy represents an advanced therapeutic approach involving the modification, replacement, inactivation, or introduction of genetic material to prevent or treat diseases at their underlying biological source. The market encompasses in vivo and ex vivo gene therapy approaches, supported by viral and non-viral delivery technologies, and is being applied across oncology, rare and genetic disorders, hematology, ophthalmology, and other therapeutic indications. The growing prevalence of cancer and inherited diseases, increasing availability of advanced gene delivery technologies, rising research funding, expanding cell and gene therapy manufacturing capabilities, and increasing regulatory approvals are accelerating the commercialization of gene-based treatments. The market is also benefiting from the growing pipeline of therapies targeting conditions with significant unmet medical needs, including spinal muscular atrophy, hemophilia, Duchenne muscular dystrophy, and inherited retinal disorders. As clinical evidence continues to demonstrate the potential of one-time or limited-administration therapies to deliver long-term therapeutic benefits, gene therapy is increasingly shifting from an emerging research field toward an important component of precision and personalized medicine.
Market growth is being driven by rapid advancements in gene editing technologies, improved vector engineering, increasing investment from pharmaceutical and biotechnology companies, and greater collaboration between industry, academia, and research institutions. The development of technologies such as CRISPR-based gene editing, adeno-associated virus vectors, lentiviral vectors, and emerging non-viral delivery systems is expanding the potential applications of gene therapy while improving the precision and efficiency of genetic material delivery. The in vivo gene therapy segment dominates the therapy type category, while ex vivo gene therapy is projected to be the fastest-growing therapy approach, supported by its controlled genetic modification capabilities and growing use in blood disorders and certain cancers. Viral vectors dominate the vector type segment, benefiting from established delivery efficiency and their extensive use in approved therapies, while non-viral vectors are emerging as an attractive area of innovation. Oncology dominates the indication segment, reflecting the expanding use of gene-based approaches in cancer treatment, whereas ophthalmology is expected to witness strong growth as gene therapies for inherited retinal disorders continue to advance. Hospitals dominate the end-use segment, supported by their specialised infrastructure and ability to manage complex treatment administration and patient monitoring. North America currently dominates the global market, backed by its advanced healthcare infrastructure, favourable regulatory environment, strong biotechnology ecosystem, and substantial R&D investment, while Asia Pacific is projected to be the fastest-growing regional market, supported by expanding healthcare infrastructure, increasing investments in biotechnology, and growing adoption of advanced therapies. Over the forecast period, the market is expected to evolve around the convergence of precision medicine, gene editing, advanced delivery technologies, AI-enabled research, and expanding clinical applications across rare diseases, oncology, and other complex conditions.
Key Highlights of the Report
• The in vivo gene therapy segment dominates the therapy type category, supported by its ability to deliver genetic material directly into the patient’s body and address diseases affecting multiple organs or systemic biological pathways.
• The ex vivo gene therapy segment is projected to be the fastest-growing therapy approach, driven by its ability to enable controlled genetic modification outside the patient’s body before the treated cells are returned to the patient.
• Viral vectors dominate the vector type segment, supported by their established gene delivery efficiency, ability to achieve stable gene expression, and extensive use across approved and clinical-stage therapies.
• Adeno-associated virus vectors remain an important technology within viral vector-based gene therapy, particularly for applications requiring targeted and efficient delivery of therapeutic genetic material.
• Non-viral vectors represent an emerging growth opportunity, supported by their potential to reduce immune-related concerns and avoid some limitations associated with viral delivery systems.
• The oncology segment dominates the indication category, driven by the increasing application of gene therapy in cancer treatment and the potential to selectively target or modify cancer cells.
• The rare and genetic disorders segment represents another major therapeutic opportunity, supported by the increasing adoption of gene therapies for inherited diseases with limited conventional treatment options.
• The ophthalmology segment is expected to witness strong growth, driven by increasing adoption of gene therapies for inherited retinal disorders and other genetic eye diseases.
• The hospitals segment dominates the end-use category, supported by specialised infrastructure, trained healthcare professionals, advanced monitoring capabilities, and the ability to manage complex gene therapy administration.
• Specialty clinics and gene therapy centers are emerging as important growth areas, particularly as demand increases for specialised treatment administration, patient monitoring, and long-term follow-up.
• North America dominates the global gene therapy market, supported by its advanced healthcare infrastructure, favourable regulatory environment, strong biotechnology ecosystem, extensive clinical research capabilities, and high levels of investment.
• Asia Pacific is projected to be the fastest-growing regional market, driven by expanding healthcare infrastructure, increasing biotechnology investment, growing clinical research activity, and rising adoption of advanced therapeutic technologies.
• The U.S. dominates the North American market, supported by its strong pharmaceutical and biotechnology industry, extensive research ecosystem, substantial funding, and favourable regulatory environment.
• Advancements in gene editing technologies are a major market growth driver, with CRISPR and other precision gene-editing approaches expanding the potential to develop targeted therapies for genetic and complex diseases.
• The increasing prevalence of rare genetic and inherited diseases is accelerating market demand, particularly for conditions where conventional treatment options remain limited or provide only symptomatic management.
• Rising investments and strategic collaborations are strengthening the market ecosystem, enabling pharmaceutical companies, biotechnology firms, academic institutions, and research organisations to accelerate therapy development and commercialisation.
• The growing number of product approvals and launches is supporting market expansion, improving clinical confidence and increasing awareness of gene therapy as a viable treatment option.
• The expansion of gene therapy applications beyond rare diseases is creating new growth opportunities, particularly across oncology, hematology, ophthalmology, neurological disorders, and other complex therapeutic areas.
• Personalised and precision gene therapies represent a major future opportunity, as advances in genetic sequencing and bioinformatics enable therapies to be developed for specific genetic mutations and patient populations.
• The development of advanced delivery technologies is becoming a key innovation focus, with viral vectors, nanoparticles, lipid-based carriers, and non-viral systems being explored to improve therapeutic precision, safety, and efficacy.
• High development and manufacturing costs remain a major market challenge, particularly due to the complexity of vector production, specialised manufacturing infrastructure, quality control requirements, and regulatory compliance.
• The complexity of gene therapy delivery represents a significant industry challenge, with developers continuing to address issues related to immune responses, vector selection, tissue targeting, durability, and potential side effects.
• Manufacturing scalability is becoming increasingly important, as the commercialisation of more gene therapies creates demand for reliable, high-capacity production and specialised cell and gene therapy manufacturing services.
• AI and advanced computational technologies are emerging as important enablers, supporting target identification, vector design, biomarker discovery, patient selection, clinical trial optimisation, and therapy development.
• Strategic partnerships, mergers, acquisitions, and licensing agreements remain important competitive strategies, enabling companies to strengthen pipelines, access innovative technologies, and accelerate commercialisation.
• The competitive landscape is led by major pharmaceutical and biotechnology companies, while emerging biotech firms continue to contribute specialised technologies and innovative approaches in gene editing, vector engineering, and precision medicine.
Key Company Profiles
• Amgen
• Bayer
• BioMarin
• Bristol Myers Squibb
• Ferring Pharmaceuticals
• Gilead Sciences
• Krystal Biotech
• Novartis
• Pfizer
• Sarepta Therapeutics
• UniQure
Data Source
Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.
